Daclatasvir D6
| Product Name | Daclatasvir D6 |
|---|---|
| Alternate Names | Daclatasvir Stable Isotopes, Stable Isotopes of Daclatasvir |
| CAT No. | CS-O-11958 |
| CAS No. | 1801709-41-0 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 744.91 g/mol |
| Mol. For. | C₄₀H₄₄D₆N₈O₆ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Daclatasvir |
| Purity | 95% |
| Therapeutic | Antiretroviral / Anti-HIV |
| Smileys | O=C(N1[C@H](C2=NC=C(C3=CC=C(C4=CC=C(C5=CN=C([C@H](CCC6)N6C([C@H](C(C)C)NC(OC([2H])([2H])[2H])=O)=O)N5)C=C4)C=C3)N2)CCC1)[C@H](C(C)C)NC(OC([2H])([2H])[2H])=O |
| Canonical Smiles | CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC |
| InchIKey | FKRSSPOQAMALKA-GXBFPSLASA-N |
| Inchl | InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1/i5D3,6D3 |
| IUPAC | trideuteriomethyl N-[(2S)-3-methyl-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-3-methyl-2-(trideuteriomethoxycarbonylamino)butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamate |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Daclatasvir D6 is a deuterium-labeled version of Daclatasvir, which is a direct-acting antiviral medication used for the treatment of chronic hepatitis C virus (HCV) infection. Daclatasvir D6 is a potent, selective, and orally active NS5A inhibitor, which means it prevents the replication of HCV by blocking the action of the non-structural protein 5A (NS5A).
The usage of Daclatasvir D6 is similar to that of Daclatasvir, and it is typically administered in combination with other antiviral agents such as sofosbuvir. The treatment regimen and dosage may vary depending on the patient's genotype and medical history. The medication is generally well-tolerated, with few side effects reported.
Chemically, Daclatasvir D6 is an isotopically labeled analog of Daclatasvir, with six deuterium atoms replacing six hydrogen atoms in the molecular structure. This labeling enhances the drug's stability and helps improve its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion.
In conclusion, Daclatasvir D6 is a useful tool for researchers and medical professionals in studying the pharmacokinetics and metabolism of Daclatasvir. Its usage in treating chronic HCV infection is similar to that of the non-labeled version and offers an effective and safe treatment option for patients.
Get an Instant Quote
Related Compounds
Daclatasvir Diethyl Ester D10 | Daclatasvir 13C2D6 |